Team
Our Founders
Move at the Speed of Experience™
Christina J. Ansted, MPH, CCMEP
Co-Founder and CEO
Christina is a multifaceted biotech executive with expertise in global commercialization, medical communications and rare disease. Adept at building high-performance teams that drive value across an organization, Christina is deeply inspired to create a legacy of innovation by changing the approach to commercialization, improving rates of success and impacting the lives of patients worldwide.
Michael C. Janes
Co-Founder and CRO
Head, Private Market Practice
Michael has led global teams focused on global business development, private equity, sales operations, training and development, and business process optimization. With a commitment to outcomes and outstanding relationship management, Michael’s vision is to drive value creation for private market clients with biotech centric portfolios.
Executive Team
Levarage a Commercial Catalyst - Industry Experts Support Value Creation Opportunities
Commercial Strategy and Clinical / Corporate Development
Andy Parratt
Early Commercialization Strategy and Planning, Therapeutics
Andy has deep commercialization expertise across a wide range of therapeutic areas and organizations ensuring that scientific innovations reach and benefit patients. He brings an integrated approach for early commercial planning encompassing R&D, market access, pricing, MR and analytics to drive the development and commercialization of assets in areas of high unmet need across US, European and global markets. Solution oriented, Andy combines operational agility with strategic focus to address meaningful challenges in healthcare.
Terry Murray
Chief Strategy Officer, Medical Technology
Terry brings more than thirty—five years of progressive experience in strategic planning, business leadership, and organizational development. He has worked extensively in Europe, Asia and across the Americas in a variety of high tech, life science and medical device environments. Terry has provided extensive guidance and execution for medical device and investor-driven start-ups seeking innovative approaches for creating market traction in emerging and established markets. Terry is the author of, “The Transformational Entrepreneur,” and a veteran of U.S. Naval Intelligence.
Paresh Soni, MD, PhD
Clinical & Corporate Development
Paresh is a board-certified internist and gastroenterologist with hepatology expertise and broad medical/scientific and corporate management experience having led clinical development programs, and global multidisciplinary teams across the development spectrum, with a proven record of multiple successful NDAs.
Finance and Business Development
Steve Sieker
Chief Financial Officer
Steve brings over 30 years of corporate experience, including more than 15 years in senior leadership roles. Beginning his career as an auditor in the Big 4, Steve has held CFO and other senior executive positions across various industries and ownership structures. As a partner at LGA, Steve leads the firm’s fractional CFO practice. Along with LGA, he offers a broader suite of financial and advisory services, including audit, tax, business valuation and outsourced accounting, ensuring comprehensive support for RCP clients.
Daniel Silver, Esq.
Chief of Staff
Dan, an attorney by training, brings his legal expertise and experience as a biotech coordinator to support daily operations of the leadership and executive teams, executive corporate administrative functions, vendor and partner relations and strategic implementation.
Global Patient and Market Access, Pricing and Reimbursement
Kevin W. Mayo, PhD, EJD
SVP, Global Market Access & Health Economics
Kevin's extensive expertise in market access, pricing and reimbursement, HEOR, health policy and government affairs, and patient/medical advocacy enables him to maximize global revenue potential and market share growth. he leads patient and market access strategy and implementation.
Rob Philo
VP, US Practice Lead Market Access
Rob is a seasoned pharmaceutical executive with diverse and progressive experience in sales and market access. He helps clients navigate the complex and competitive U.S. payer landscape to optimize patient access and revenue potential. With a focus on the patient, Rob has successfully developed and executed national access strategies for major payers, PBMs, and government programs, resulting in significant market share and sales growth for innovative products.
Jennifer King, MBA
VP, Global Pricing & Payer Insights
Jennifer brings a wealth of commercial and market access experience across oncology and orphan drugs. She is well-versed in global, EMEA and Asia Pacific/Japan markets supporting pricing and market access strategies in both strategic development and implementation with the goal of achieving optimal access for all stakeholders.
Art Vrecenak, PhD, MBA
Managed Markets Access
Principal at Access Acumen, Art has broad experience across field sales, health economics, product management, clinical development, hospital/GPO marketing, national HMO marketing, national PBM marketing, strategic customer marketing, and generic product business strategy. He has developed and led teams tasked with value proposition development and communication for both pharma benefit and medical benefit products. This depth and breadth of experience feeds a passion for optimizing product performance throughout the product life.
Medical Affairs and Diagnostic Strategy
Radhika Tripuraneni, MD, MPH
Chief Medical Officer
Radhika brings extensive medical affairs experience that applies a business strategy to the medical need. Her expertise covering all areas of medical affairs (including scientific communications, health policy/economics) has built and expanded various market areas. A veteran of the biotech industry, her experience includes clinical development and operations, and biometrics. Radhika's formidable acumen in both medical affairs and the business of commercialization is a rare combination that drives tangible value and outcomes.
Terry Granec, MSc
Chief Collaboration Officer, Medical Affairs and Commercial Strategy
Terry is a seasoned and respected biopharma veteran bringing 25 years of unique cross functional experience across Medical Affairs, Commercial, and Diagnostic Strategy specializing in rare and ultra-rare diseases. Recognized for his collaborative approach, he is adept in aligning medical affairs and commercial strategy to facilitate successful product launches. Terry has led medical affairs and field sales teams in multiple biopharma companies from large & mid cap to privately held biotech startups.
Pannie Trifillis, PhD
SVP, Medical Affairs and Scientific Communications
Pannie is a passionate biopharma executive with 25 years' experience in the discovery, development and commercialization of therapies for rare, genetic diseases. A cross-functional leader, Pannie has deep and broad expertise in medical affairs omnichannel strategy, KOL/DOL engagement, scientific and medical communications, congress planning, publication strategy, advisory boards, real-world evidence generation, internal training and medical information. She has been instrumental in facilitating access to treatment for patients globally.
Tom Lo, MSc
ED, Clinical Science, Diagnostics and Strategic Partnerships
Tom has exceptional experience expanding the treatable patient population for therapeutics. With a focus on building awareness for diagnostic testing to enable optimal patient identification and timely therapy, Tom has led diagnostic strategy for eight rare diseases and provided leadership to develop and implement diagnostic strategy supporting field implementation and training across a myriad of therapeutic areas. He applies his considerable field sales acumen to ensure successful collaboration, integration, and execution of strategic diagnostic initiatives.
Ramin Pourfarzib, PhD
Field-Based Medical Affairs
Ray has led medical, clinical affairs and medical scientific liaison teams. He provides strategic support for national advisory boards and speaker development programs as well as medical and scientific training and management of field-based scientific resources. Experienced in the implementation of clinical research studies and publications, Ray also assists with thought leader and investigator relationship management.
Multidisciplinary Strategic Advisors
Kelly DeAngelis
Public Relations & Communications
Founder and President at Pilcrow Group, Kelly is an award-winning communications and public relations leader with extensive experience creating and executing strategic communications plans that drive engagement and visibility. She has a proven track record of building and leading high-performing teams and is passionate about helping companies tell their stories.
Safia Rizvi, PhD
Early Commercial Development
CEO of CILA Therapeutics, Safia is a life science business executive and entrepreneur with more than 20 years of experience in all aspects of the biotech/pharma value chain, from discovery to commercialization. A former computational biologist with a deep understanding of AI data, informatics, clinical trials and market access, she is highly skilled at transitioning scientific concepts into product pipelines and has served as a strategic advisory for biopharma CEOs and leadership teams.
Victoria Danilchouk
International Expansion, Commercialization Strategy and Digital Health
Based in Brussels, Belgium, Victoria is an industry veteran and senior advisor with expertise in commercial strategy, product management and market access. She specializes in new product strategy, commercialization, pricing, reimbursement, partnerships, with a special focus on global expansion and commercialization strategies for Europe, LATAM, MENA and APAC. Founder of Pretium Strategy, Victoria’s proficiency spans multiple therapeutic areas across both medicines and medical devices, including digital health solutions and digital therapeutics.
Katherin Rubino, PharmD, JD
Intellectual Property Law
Partner and Chair of the Life Sciences Practice Group at Caldwell, Katie is a trained pharmacist and accomplished patent attorney who guides clients to achieve business objectives through strategic portfolio curation and monetization strategies. She works with VC-backed biotech, chemical, pharma and other life-science companies to develop global IP portfolio strategies tailored to business goals. Katie is Chair of the Chemistry and the Law division of the American Chemical Society and provides pro-bono legal advice to MIT Sandbox and MassChallenge.
Andy S. Verderame, MBA, RAC
U.S. Regulatory Affairs
As owner of FDA Regulatory, LLC, Andy is experienced in all aspects of U.S. regulatory affairs and FDA interactions. He has been an active and highly respected member of the regulatory community for decades and has personally led over 100 meetings with the FDA, managed multi-site global regulatory teams for both large and small pharma, and led preparations and presentations to FDA Advisory Committees with successful outcomes. Of note, Andy was the first industry representative invited to speak at the FDA Project Manager Forum.
Stephen F. Amato, PhD, MBA
Global Regulatory Affairs
Steve is a global regulatory affairs expert with vast experience in the healthcare sector. With a strategically oriented, collaborative and evidence-based approach, he has worked directly with the FDA and developed strategies for medical device and biopharmaceutical products. Steve is principal advisor and chief strategist at tJûn17 Life Science Advisors and serves as Department Chair and Professor of Regulatory Affairs and Quality Assurance at Northeastern University College of Professional Studies.
Greg Fuest
Global Commercialization Strategy
Greg is an exceptional marketing and commercial strategy executive with extensive experience in large pharma and startup biotech companies leading cross-functional teams for pre-launch, launch, re-launch and in-market brands in primary care, oncology, virology, respiratory, ERT, gene therapy and rare disease, globally and in the U.S., in addition to notable divisional/regional sales management expertise.